EUVIMEDEUVIMED entdecken
Fallbericht

Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma

Tyra Reed, Steven Rivera iD, Craig Fisher, William Schaffenburg

Journal of Cutaneous Pathology · 2025-04 · 52 (4) · 278-283

DOI: 10.1111/cup.14778 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 03.01.2025. Verfasst von Tyra Reed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Uniformed Services University School of Medicine, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Melanoma, Panniculitis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Panniculitides are a group of inflammatory disorders of the subcutaneous fat that have been reported as a rare complication of both a serine threonine kinase BRAF inhibitor monotherapy and BRAF inhibition in combination with a mitogen activated protein kinase (MEK) inhibitor combination therapy used to treat metastatic melanoma. The cutaneous manifestations of BRAF and BRAF/MEK therapies have been well documented, but neutrophilic panniculitis remains a less common complication with fewer case reports. Physician awareness of this complication when following patients on similar targeted therapies can decrease delays in appropriate management. We report a case of one patient who developed neutrophilic panniculitis during treatment with the BRAF/MEK combination of dabrafenib and trametinib. We followed the patient from initial presentation in the emergency department to diagnosis to include pathology findings of the disease. In this case of neutrophilic panniculitis, the patient presented with a history of stage IIIa (pT2a N1a M0) cutaneous melanoma of the right flank and developed classic painful nodules on the lower legs and arms with associated fever within the first 2 weeks after initiating adjuvant melanoma targeted therapy. The biopsies showed a mixed, neutrophilic panniculitis, without overlying epidermal changes. Given the patient's clinical history, the biopsy was consistent with a BRAF inhibitor induced neutrophilic panniculitis. The panniculitis resolved with symptomatic care and the patient was maintained on the antitumor therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsMelanomaPanniculitisProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSkin NeoplasmsHumansImidazolesCutaneous Malignant MelanomaNeutrophilsOximesPyridonesPyrimidinones

Substanzen

BRAF protein, humandabrafenibImidazolesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinib

Autor:innen und Institutionen

  • Uniformed Services University School of Medicine, Bethesda, Maryland, USA.
  • Department of Dermatology, San Antonio Uniformed Services Health Consortium (SAUSHEC), San Antonio, Texas, USA.

ORCID-Profile: Steven Rivera

Zitieren

APA

Reed, T., Rivera, S., Fisher, C., & Schaffenburg, W. (2025). Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma. Journal of Cutaneous Pathology, 52(4), 278-283. https://doi.org/10.1111/cup.14778

Vancouver

Reed T, Rivera S, Fisher C, Schaffenburg W. Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma. Journal of Cutaneous Pathology. 2025;52(4):278-283. doi:10.1111/cup.14778

BibTeX
@article{Reed2025,
  author = {Reed, Tyra and Rivera, Steven and Fisher, Craig and Schaffenburg, William},
  title = {Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  volume = {52},
  number = {4},
  pages = {278--283},
  doi = {10.1111/cup.14778}
}
Kostenlos starten →